US RNA Analysis Market to Reach USD 15.59 Billion by 2032, Growing at a CAGR of 11.37% During 2026–2032

The United States RNA Analysis Market was valued at USD 7.77 billion in 2025 and is projected to grow from USD 8.17 billion in 2026 to USD 15.59 billion by 2032, expanding at a CAGR of 11.37% during the forecast period. This robust growth trajectory is anchored in the accelerating integration of RNA sequencing into precision oncology workflows, sustained federal funding commitments to genomic research, and a rapidly expanding pipeline of RNA-based therapeutics requiring continuous transcriptomic analysis services.

Federal investment in RNA biology provides a direct structural underpinning for the market. In June 2024, the NIH, in partnership with the NSF, announced approximately USD 15.4 million in joint funding for RNA research and technology development. Additionally, the National Cancer Institute (NCI) launched the RNA Modifications Driving Oncogenesis (RNAMoDO) initiative in 2024, channeling resources into laboratory consumables, instruments, and bioinformatics platforms that constitute the market’s supply base.

Consequently, the US RNA analysis market is positioned for sustained growth, driven by converging forces of oncology demand, government funding, and private investment. The dominance of reagents and consumables at approximately 55% share, alongside next-generation sequencing (NGS) technologies commanding approximately 46% of the technology segment, ensures a structurally resilient revenue base through 2032, as stated in the recent report “US RNA Analysis Market”.

US RNA Analysis Market Highlights

The US RNA Analysis Market, valued at USD 7.77 billion in 2025, is projected to grow to USD 8.17 billion in 2026 and reach USD 15.59 billion by 2032, at a CAGR of 11.37%.
Reagents and consumables dominate with approximately 55% share, driven by recurring per-experiment consumption of extraction kits, reverse transcription reagents, and library preparation consumables across all end-users.
Sequencing technologies (NGS) lead by technology at approximately 46% share, valued for simultaneous whole-transcriptome profiling at single-nucleotide resolution unachievable by PCR or microarray platforms.
The market is moderately consolidated, with the top 5 players collectively holding 19% share, reflecting coexistence of global platform leaders alongside specialized reagent suppliers and AI-native transcriptomics firms.